Pulmonary administration of small interfering RNA: The route to go?

Journal of Controlled Release

Volumn 235, Issue , 2016, Pages 14-23

  Ruigrok, M J R ^a   Frijlink, H W ^a   Hinrichs, W L J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Animals; Drug carriers; Gene silencing; Inhalation; RNA interference; siRNA

Indexed keywords

ANIMALS; CONTROLLED DRUG DELIVERY; GENE EXPRESSION; GENETIC ENGINEERING; PHYSIOLOGY; RNA; TARGETED DRUG DELIVERY;

DRUG CARRIER; GENE SILENCING; INHALATION; RNA INTERFERENCE; SIRNA;

GENE THERAPY;

DRUG CARRIER; SMALL INTERFERING RNA; VIRUS VECTOR;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; DRY POWDER INHALER; GENERAL PATHOLOGY; HUMAN; INHALER; METERED DOSE INHALER; NEBULIZER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RESPIRATORY DRUG ADMINISTRATION; RESPIRATORY FUNCTION; RESPIRATORY SYSTEM; RNAI THERAPEUTICS; SOFT MIST INHALER; VIRAL GENE DELIVERY SYSTEM; ANATOMY AND HISTOLOGY; ANIMAL; GENE TRANSFER; INHALATIONAL DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, INHALATION; ANIMALS; GENE TRANSFER TECHNIQUES; HUMANS; RESPIRATORY SYSTEM; RNA, SMALL INTERFERING;

EID: 84971236408     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.05.054     Document Type: Review

References (79)

1. M.A. Kutzler, and D.B. Weiner DNA vaccines: ready for prime time? Nat. Rev. Genet. 9 2008 776 788 10.1038/nrg2432
2. R.W. Carthew, and E.J. Sontheimer Origins and mechanisms of miRNAs and siRNAs Cell 136 2009 642 655 10.1016/j.cell.2009.01.035
3. D.B.T. Cox, R.J. Platt, and F. Zhang Therapeutic genome editing: prospects and challenges Nat. Med. 21 2015 121 131 10.1038/nm.3793
4. A. Wittrup, and J. Lieberman Knocking down disease: a progress report on siRNA therapeutics Nat. Rev. Genet. 16 2015 543 552 10.1038/nrg3978
5. Z. Li, and T.M. Rana Therapeutic targeting of microRNAs: current status and future challenges Nat. Rev. Drug Discov. 13 2014 622 638 10.1038/nrd4359
6. J.K.W. Lam, M.Y.T. Chow, Y. Zhang, and S.W.S. Leung siRNA versus miRNA as therapeutics for gene silencing Mol. Ther. Nucleic Acids 4 2015 e252 10.1038/mtna.2015.23
7. Y. Chen, D. Gao, and L. Huang In vivo delivery of miRNAs for cancer therapy: challenges and strategies Adv. Drug Deliv. Rev. 81 2015 128 141 10.1016/j.addr.2014.05.009
8. D.M. Dykxhoorn, D. Palliser, and J. Lieberman The silent treatment: siRNAs as small molecule drugs Gene Ther. 13 2006 541 552 10.1038/sj.gt.3302703
9. O.M. Merkel, I. Rubinstein, and T. Kissel siRNA delivery to the lung: what's new? Adv. Drug Deliv. Rev. 75 2014 112 128 10.1016/j.addr.2014.05.018
10. M.R. Zamora, M. Budev, M. Rolfe, J. Gottlieb, A. Humar, J. DeVincenzo, and et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus Am. J. Respir. Crit. Care Med. 183 2011 531 538 10.1164/rccm.201003-0422OC
11. A. Tsuda, F.S. Henry, and J.P. Butler Gas and aerosol mixing in the acinus Respir. Physiol. Neurobiol. 163 2008 139 149 10.1016/j.resp.2008.02.010
12. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 2010 1 19 10.1016/j.ijpharm.2010.03.017
13. W.C. Aird Phenotypic heterogeneity of the endothelium: II. Representative vascular beds Circ. Res. 100 2007 174 190 10.1161/01.RES.0000255690.03436.ae
14. R. Katre, S.K. Burns, H. Murillo, M.J. Lane, and C.S. Restrepo Anomalous pulmonary venous connections Semin. Ultrasound, CT MRI 33 2012 485 499 10.1053/j.sult.2012.07.001
15. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications Br. J. Clin. Pharmacol. 56 2003 588 599 10.1046/j.1365-2125.2003.01892.x
16. W.F. Tonnis, G.F. Kersten, H.W. Frijlink, W.L.J. Hinrichs, A.H. de Boer, and J.-P. Amorij Pulmonary vaccine delivery: a realistic approach? J. Aerosol Med. Pulm. Drug Deliv. 25 2012 249 260 10.1089/jamp.2011.0931
17. J. Jacquot, A. Hayem, and C. Galabert Functions of proteins and lipids in airway secretions Eur. Respir. J. 5 1992 343 358
18. G.M. Cohen Pulmonary metabolism of foreign compounds: its role in metabolic activation Environ. Health Perspect. 85 1990 31 41 10.2307/3430663
19. Z. Chen, C.M. Fillmore, P.S. Hammerman, C.F. Kim, and K.-K. Wong Non-small-cell lung cancers: a heterogeneous set of diseases Nat. Rev. Cancer 14 2014 535 546 10.1038/nrc3775
20. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2016 CA Cancer J. Clin. 66 2016 7 30 10.3322/caac.21332
21. M.W. Lee, D.S. Kim, J.H. Lee, B.S. Lee, S.H. Lee, H.L. Jung, and et al. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration Cancer Sci. 102 2011 1822 1828 10.1111/j.1349-7006.2011.02025.x
22. H.-L.L. Jiang, S.-H.H. Hong, Y.-K.K. Kim, M.A. Islam, H.-J.J. Kim, Y.-J.J. Choi, and et al. Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy Int. J. Pharm. 420 2011 256 265 10.1016/j.ijpharm.2011.08.045
23. H.-L. Jiang, K. Hong, S. Kim, C.-S. Cho, and et al. Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1 Int. J. Nanomedicine 7 2012 2293 10.2147/IJN.S29152
24. S.-K. Hwang, S.-H. Chang, A. Minai-Tehrani, Y.-S. Kim, and M.-H. Cho Lentivirus-AIMP2-DX2 shRNA suppresses cell proliferation by regulating Akt1 signaling pathway in the lungs of AIMP2(+)/(-) mice J. Aerosol Med. Pulm. Drug Deliv. 26 2013 165 173 10.1089/jamp.2011.0959
25. C.-X. Xu, D. Jere, H. Jin, S.-H. Chang, Y.-S. Chung, J.-Y. Shin, and et al. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis Am. J. Respir. Crit. Care Med. 178 2008 60 73 10.1164/rccm.200707-1022OC
26. D. Jere, C.-X. Xu, R. Arote, C.-H. Yun, M.-H. Cho, and C.-S. Cho Poly(beta-amino ester) as a carrier for si/shRNA delivery in lung cancer cells Biomaterials 29 2008 2535 2547 10.1016/j.biomaterials.2008.02.018
27. W. McKleroy, T.-H. Lee, and K. Atabai Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis AJP Lung Cell. Mol. Physiol. 304 2013 L709 L721 10.1152/ajplung.00418.2012
28. M. Selman, V. Ruiz, S. Cabrera, L. Segura, R. Ramírez, R. Barrios, and et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am. J. Physiol. Lung Cell. Mol. Physiol. 279 2000 L562 L574
29. R.C.A. Dancer, A.M. Wood, and D.R. Thickett Metalloproteinases in idiopathic pulmonary fibrosis Eur. Respir. J. 38 2011 1461 1467 10.1183/09031936.00024711
30. J.K. Taubenberger, and D.M. Morens The pathology of influenza virus infections Annu. Rev. Pathol. Mech. Dis. 3 2008 499 522 10.1146/annurev.pathmechdis.3.121806.154316
31. L. Gillim-Ross, and K. Subbarao Emerging respiratory viruses: challenges and vaccine strategies Clin. Microbiol. Rev. 19 2006 614 636 10.1128/CMR.00005-06
32. Q. Ge, M.T. McManus, T. Nguyen, C.-H. Shen, P.A. Sharp, H.N. Eisen, and et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription Proc. Natl. Acad. Sci. 100 2003 2718 2723 10.1073/pnas.0437841100
33. S.M. Tompkins, C.-Y. Lo, T.M. Tumpey, and S.L. Epstein Protection against lethal influenza virus challenge by RNA interference in vivo Proc. Natl. Acad. Sci. U. S. A. 101 2004 8682 8686 10.1073/pnas.0402630101
34. H.W. Frijlink, and A.H. De Boer Dry powder inhalers for pulmonary drug delivery Expert Opin. Drug Deliv. 1 2004 67 86 10.1517/17425247.1.1.67
35. T.C. Carvalho, J.I. Peters, and R.O. Williams III Influence of particle size on regional lung deposition - what evidence is there? Int. J. Pharm. 406 2011 1 10 10.1016/j.ijpharm.2010.12.040
36. M. Hoppentocht, P. Hagedoorn, H.W. Frijlink, and A.H. de Boer Technological and practical challenges of dry powder inhalers and formulations Adv. Drug Deliv. Rev. 75 2014 18 31 10.1016/j.addr.2014.04.004
37. P. Demoly, P. Hagedoorn, A.H. de Boer, and H.W. Frijlink The clinical relevance of dry powder inhaler performance for drug delivery Respir. Med. 108 2014 1195 1203 10.1016/j.rmed.2014.05.009
38. A.H. de Boer, D. Gjaltema, P. Hagedoorn, and H.W. Frijlink Can "extrafine" dry powder aerosols improve lung deposition? Eur. J. Pharm. Biopharm. 96 2015 143 151 10.1016/j.ejpb.2015.07.016
39. R.L. Juliano, X. Ming, K. Carver, and B. Laing Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology Nucleic Acid Ther. 24 2014 101 113 10.1089/nat.2013.0463
40. A.K. Varkouhi, M. Scholte, G. Storm, and H.J. Haisma Endosomal escape pathways for delivery of biologicals J. Control. Release 151 2011 220 228 10.1016/j.jconrel.2010.11.004
41. J. Gilleron, W. Querbes, A. Zeigerer, A. Borodovsky, G. Marsico, U. Schubert, and et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape Nat. Biotechnol. 31 2013 638 646 10.1038/nbt.2612
42. D. Lu, and A.J. Hickey Pulmonary vaccine delivery Expert Rev. Vaccines. 6 2007 213 226 10.1586/14760584.6.2.213
43. W.F. Tonnis, A.J. Lexmond, H.W. Frijlink, A.H. de Boer, and W.L. Hinrichs Devices and formulations for pulmonary vaccination Expert Opin. Drug Deliv. 10 2013 1383 1397 10.1517/17425247.2013.810622
44. H.W. Frijlink, and A.H. de Boer Trends in the technology-driven development of new inhalation devices Drug Discov. Today Technol. 2 2005 47 57 10.1016/j.ddtec.2005.05.020
45. C. Kleinstreuer, Z. Zhang, and J.F. Donohue Targeted drug-aerosol delivery in the human respiratory system Annu. Rev. Biomed. Eng. 10 2008 195 220 10.1146/annurev.bioeng.10.061807.160544
46. T. Sou, E.N. Meeusen, M. de Veer, D.A.V. Morton, L.M. Kaminskas, and M.P. McIntosh New developments in dry powder pulmonary vaccine delivery Trends Biotechnol. 29 2011 191 198 10.1016/j.tibtech.2010.12.009
47. R. Hatley, and J. Pritchard Comment on: Devices and formulations for pulmonary vaccination Expert Opin. Drug Deliv. 10 2013 1593 1595 10.1517/17425247.2013.833181
48. M. Chow, and J. Lam Dry powder formulation of plasmid DNA and siRNA for inhalation Curr. Pharm. Des. 21 2015 3854 3866 10.2174/1381612821666150820105916
49. I. Trapani, A. Puppo, and A. Auricchio Vector platforms for gene therapy of inherited retinopathies Prog. Retin. Eye Res. 43 2014 108 128 10.1016/j.preteyeres.2014.08.001
50. D.R. Deyle, and D.W. Russell Adeno-associated virus vector integration Curr. Opin. Mol. Ther. 11 2009 442 447
51. R. Waehler, S.J. Russell, and D.T. Curiel Engineering targeted viral vectors for gene therapy Nat. Rev. Genet. 8 2007 573 587 10.1038/nrg2141
52. M. Thomas, J.J. Lu, J. Chen, and A.M. Klibanov Non-viral siRNA delivery to the lung Adv. Drug Deliv. Rev. 59 2007 124 133 10.1016/j.addr.2007.03.003
53. D. Castanotto, and J.J. Rossi The promises and pitfalls of RNA-interference-based therapeutics Nature 457 2009 426 433 10.1038/nature07758
54. M. Kapoor, D.J. Burgess, and S.D. Patil Physicochemical characterization techniques for lipid based delivery systems for siRNA Int. J. Pharm. 427 2012 35 57 10.1016/j.ijpharm.2011.09.032
55. O.M. Merkel, and T. Kissel Nonviral Pulmonary Delivery of siRNA Acc. Chem. Res. 45 2012 961 970 10.1021/ar200110p
56. H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, and D.G. Anderson Non-viral vectors for gene-based therapy Nat. Rev. Genet. 15 2014 541 555 10.1038/nrg3763
57. L. Chronopoulou, M. Massimi, M.F. Giardi, C. Cametti, L.C. Devirgiliis, M. Dentini, and et al. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures Colloids Surfaces B Biointerfaces. 103 2013 310 317 10.1016/j.colsurfb.2012.10.063
58. N. Sanders, C. Rudolph, K. Braeckmans, S.C. De Smedt, and J. Demeester Extracellular barriers in respiratory gene therapy Adv. Drug Deliv. Rev. 61 2009 115 127 10.1016/j.addr.2008.09.011
59. A.G. Rosas-Taraco, D.M. Higgins, J. Sánchez-Campillo, E.J. Lee, I.M. Orme, M. González-Juarrero, and et al. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis Am. J. Respir. Cell Mol. Biol. 41 2009 136 145 10.1165/rcmb.2008-0363OC
60. S. Moschos, M. Frick, B. Taylor, P. Turnpenny, H. Graves, K.G. Spink, and et al. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense Mol. Ther. 19 2011 2163 2168 10.1038/mt.2011.206
61. S.-K. Hwang, A. Minai-Tehrani, H.-T. Lim, J.-Y. Shin, G.-H. An, K.-H. Lee, and et al. Decreased level of PDCD4 (programmed cell death 4) protein activated cell proliferation in the lung of A/J mouse J. Aerosol Med. Pulm. Drug Deliv. 23 2010 285 293 10.1089/jamp.2009.0778
62. O.B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A.A. Vetcher, V.A. Soldatenkov, and et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug Pharm. Res. 26 2009 382 394 10.1007/s11095-008-9755-4
63. H.-L. Jiang, C.-X. Xu, Y.-K. Kim, R. Arote, D. Jere, H.-T. Lim, and et al. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway Biomaterials 30 2009 5844 5852 10.1016/j.biomaterials.2009.07.017
64. D.E. Zamora-Avila, P. Zapata-Benavides, M.A. Franco-Molina, S. Saavedra-Alonso, L.M. Trejo-Avila, D. Reséndez-Pérez, and et al. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth Cancer Gene Ther. 16 2009 892 899 10.1038/cgt.2009.35
65. E.J.B. Nielsen, J.M. Nielsen, D. Becker, A. Karlas, H. Prakash, S.Z. Glud, and et al. Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles Pharm. Res. 27 2010 2520 2527 10.1007/s11095-010-0255-y
66. A. Beyerle, A. Braun, O. Merkel, F. Koch, T. Kissel, and T. Stoeger Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice J. Control. Release 151 2011 51 56 10.1016/j.jconrel.2010.12.017
67. O. Taratula, O.B. Garbuzenko, A.M. Chen, and T. Minko Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA J. Drug Target. 19 2011 900 914 10.3109/1061186X.2011.622404
68. T. Okuda, D. Kito, A. Oiwa, M. Fukushima, D. Hira, and H. Okamoto Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique Biol. Pharm. Bull. 36 2013 1183 1191 10.1248/bpb.b13-00167
69. G. Shim, H.-W. Choi, S. Lee, J. Choi, Y.H. Yu, D.-E. Park, and et al. Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes Mol. Ther. 21 2013 816 824 10.1038/mt.2013.10
70. L. De Backer, T. Naessens, S. De Koker, E. Zagato, J. Demeester, J. Grooten, and et al. Hybrid pulmonary surfactant-coated nanogels mediate efficient in vivo delivery of siRNA to murine alveolar macrophages J. Control. Release 217 2015 53 63 10.1016/j.jconrel.2015.08.030
71. M.J.R. Ruigrok, and E.C.M. de Lange Emerging insights for translational pharmacokinetic and pharmacokinetic-pharmacodynamic studies: towards prediction of nose-to-brain transport in humans AAPS J. 17 2015 493 505 10.1208/s12248-015-9724-x
72. B. Davies, and T. Morris Physiological parameters in laboratory animals and humans Pharm. Res. 10 1993 1093 1095 10.1023/A:1018943613122
73. S.-A. Cryan, N. Sivadas, and L. Garcia-Contreras In vivo animal models for drug delivery across the lung mucosal barrier Adv. Drug Deliv. Rev. 59 2007 1133 1151 10.1016/j.addr.2007.08.023
74. E. Fröhlich, and S. Salar-Behzadi Toxicological assessment of inhaled nanoparticles: role of in vivo, ex vivo, in vitro, and in silico studies Int. J. Mol. Sci. 15 2014 4795 4822 10.3390/ijms15034795
75. C. a Fernandes, R. Vanbever, Preclinical models for pulmonary drug delivery., Expert Opin. Drug Deliv. 6 (2009) 1231-1245. doi:10.1517/17425240903241788.
76. J.-P. Morin, J.-M. Baste, A. Gay, C. Crochemore, C. Corbière, and C. Monteil Precision cut lung slices as an efficient tool for in vitro lung physio-pharmacotoxicology studies Xenobiotica 43 2013 63 72 10.3109/00498254.2012.727043
77. D.M.K. Jensen, D. Cun, M.J. Maltesen, S. Frokjaer, H.M.M. Nielsen, and C. Foged Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation J. Control. Release 142 2010 138 145 10.1016/j.jconrel.2009.10.010
78. D.K. Jensen, L.B. Jensen, S. Koocheki, L. Bengtson, D. Cun, H.M.M. Nielsen, and et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA J. Control. Release 157 2012 141 148 10.1016/j.jconrel.2011.08.011
79. W. Liang, M.Y.T. Chow, P.N. Lau, Q.T. Zhou, P.C.L. Kwok, G.P.H. Leung, and et al. Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus Mol. Pharm. 12 2015 910 921 10.1021/mp500745v